TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35863498

Group type: EXPERIMENTAL
Intervention: Aquablation (2 or more passes)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Aquablation (1 pass)
Number of subjects: 127
Study: 34528337

Group type: EXPERIMENTAL
Intervention: H. pylori eradication therapy (7 days of omeprazole + amoxicillin followed by 7 days of omeprazole + clarithromycin + metronidazole)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 61
Study: 33089699

Group type: EXPERIMENTAL
Intervention: Cognitive Stimulation Therapy (CST)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 112
Study: 35852693

Group type: EXPERIMENTAL
Intervention: Elastic silicone occlusive sheeting
Number of subjects: 61

Group type: COMPARATOR
Intervention: Silicone occlusive sheeting
Number of subjects: 61
Study: 34289038

Group type: EXPERIMENTAL
Intervention: Daratumumab-based therapies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Daratumumab-based therapies with ≥CR and MRD negativity
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study: 36478192

Group type: EXPERIMENTAL
Intervention: Active distraction using video games on a tablet device and wireless joystick (VG)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Passive distraction using video on tablet and wireless headphones (AV)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Basic behavior guidance technique Tell Show Do (C)
Number of subjects: 105
Study: 33169240

Group type: EXPERIMENTAL
Intervention: Citicoline 10 mg/kg/12h IV for 6 weeks plus supportive measures
Number of subjects: 80

Group type: COMPARATOR
Intervention: Supportive measures only (Control group)
Number of subjects: 80
Study: 35575420

Group type: EXPERIMENTAL
Intervention: Ertugliflozin in amorphous form
Number of subjects: 16

Group type: COMPARATOR
Intervention: Ertugliflozin in cocrystal form
Number of subjects: 16
Study: 34750484

Group type: EXPERIMENTAL
Intervention: CAVI (interventional valve implantation into the inferior vena cava using an Edwards Sapien XT valve)
Number of subjects: 28

Group type: COMPARATOR
Intervention: OMT (optimal medical therapy)
Number of subjects: 28
Study: 32597035

Group type: EXPERIMENTAL
Intervention: Milk Fat Globule Membrane (MFGM) supplementation (n=12)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo (PLA) (n=12)
Number of subjects: 25
Study: 32455493

Group type: EXPERIMENTAL
Intervention: Prehydration with 1.5 L of water within 1 hour before uroflowmetry
Number of subjects: 74

Group type: COMPARATOR
Intervention: Non-prehydrated group
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Prehydration
Number of subjects: 74
Study: 32103603

Group type: EXPERIMENTAL
Intervention: Autologous skin cell suspension (ASCS) + compression therapy
Number of subjects: 52

Group type: COMPARATOR
Intervention: Standard compression therapy (Control)
Number of subjects: 52
Study: 615704460

Group type: EXPERIMENTAL
Intervention: 600 mg of ALA administered to recipients and graft perfused with 600 mg of ALA 1 hour before surgery
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 26
Study: 34461131

Group type: EXPERIMENTAL
Intervention: EDTA decalcification
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control samples
Number of subjects: 29
Study: 32948109

Group type: EXPERIMENTAL
Intervention: Older adults
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Insomnia severity
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 145
Study: 34769925

Group type: EXPERIMENTAL
Intervention: Choline-based multi-ingredient supplementation (CMS)
Number of subjects: 14
Study: 34524631

Group type: EXPERIMENTAL
Intervention: Yoga intervention (8-week program, delivered virtually via Zoom)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 44
Study: 35920936

Group type: EXPERIMENTAL
Intervention: 0.1 mg ICG
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 0.025 mg ICG
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 0.25 mg ICG
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 2.5 mg ICG
Number of subjects: 64
Study: 33288495

Group type: EXPERIMENTAL
Intervention: Low-fat vegan diet
Number of subjects: 68
Study: 32026759

Group type: EXPERIMENTAL
Intervention: Conversation cues
Number of subjects: 587

Group type: EXPERIMENTAL
Intervention: Community cues
Number of subjects: 587

Group type: COMPARATOR
Intervention: No cue control
Number of subjects: 587
Study: 36127689

Group type: EXPERIMENTAL
Intervention: LyssnCBT
Number of subjects: 1875
Study: 35348084

Group type: EXPERIMENTAL
Intervention: Nonimage-guided CEIs
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Ultrasonography-guided CEIs
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Fluoroscopy-guided CEIs
Number of subjects: 45

Group type: COMPARATOR
Intervention: All groups (Nonimage, Ultrasonography, Fluoroscopy)
Number of subjects: 45
Study: 35655234

Group type: EXPERIMENTAL
Intervention: 6% Hydroxyethyl Starch (HES) 130 solution (Volulyte 6%)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Electrolyte solution (Ionolyte)
Number of subjects: 350
Study: 35308505

Group type: EXPERIMENTAL
Intervention: Vitamin D3 3000 IU/d oral spray supplementation
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo (xylitol, water, mint)
Number of subjects: 125
Study: 35297721

Group type: EXPERIMENTAL
Intervention: Icon arrays
Number of subjects: 131

Group type: COMPARATOR
Intervention: Numerical information
Number of subjects: 131
Study: 32638427

Group type: EXPERIMENTAL
Intervention: Laser lancing device (LMT‐3000)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional needle lancet
Number of subjects: 40
Study: 37071202

Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional exercise program
Number of subjects: 36
Study: 33620551

Group type: EXPERIMENTAL
Intervention: Daily intake of a multivitamin tablet with 150 μg of iodine
Number of subjects: 200

Group type: COMPARATOR
Intervention: Daily intake of a multivitamin tablet without iodine
Number of subjects: 200
Study: 32656994

Group type: EXPERIMENTAL
Intervention: 12 coaching calls, buddy training, primary care provider progress reports
Number of subjects: 562

Group type: COMPARATOR
Intervention: 24 coaching calls
Number of subjects: 562
Study: 616619992

Group type: EXPERIMENTAL
Intervention: Female peer mentors
Number of subjects: 150

Group type: COMPARATOR
Intervention: Male peer mentors
Number of subjects: 150

Group type: COMPARATOR
Intervention: No mentors
Number of subjects: 150
Study: 35523062

Group type: EXPERIMENTAL
Intervention: Exergaming
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional Rehabilitation (CR)
Number of subjects: 30
Study: 34602388

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen combined with alprostadil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 35312650

Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich drink (group A)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Placebo drink (group B)
Number of subjects: 153

Group type: COMPARATOR
Intervention: No drink (control group C)
Number of subjects: 153
Study: 32233961

Group type: EXPERIMENTAL
Intervention: MenACYW-TT
Number of subjects: 301

Group type: COMPARATOR
Intervention: MPSV4
Number of subjects: 301
Study: 33834354

Group type: EXPERIMENTAL
Intervention: Lubiprostone sprinkle 24 μg BID
Number of subjects: 522

Group type: EXPERIMENTAL
Intervention: Lubiprostone capsule 24 μg BID
Number of subjects: 522

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 522
Study: 32980142

Group type: EXPERIMENTAL
Intervention: Norepinephrine 5 μg.mL−1 (n = 40)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Epinephrine 5 μg.mL−1 (n = 40)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Phenylephrine 100 μg.mL−1 (n = 40)
Number of subjects: 160

Group type: COMPARATOR
Intervention: 0.9% saline infusions (n = 40)
Number of subjects: 160
Study: 35771219

Group type: EXPERIMENTAL
Intervention: Home-based leg heat therapy (HT) using water-circulating trousers, 90 min/session, 7 days/week for 8 weeks
Number of subjects: 34

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 34
Study: 34795398

Group type: EXPERIMENTAL
Intervention: Smartphone-delivered wound assessment tool
Number of subjects: 492
Study: 35918716

Group type: EXPERIMENTAL
Intervention: 3-D printed models during lectures
Number of subjects: 16

Group type: COMPARATOR
Intervention: Didactic lectures only
Number of subjects: 16
Study: 37005698

Group type: EXPERIMENTAL
Intervention: 12-week education and tailored exercise intervention (TEMPO)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual care and written information
Number of subjects: 50
Study: 32912633

Group type: EXPERIMENTAL
Intervention: Relugolix 10 mg
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Relugolix 20 mg
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Relugolix 40 mg
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Leuprorelin 3.75 mg
Number of subjects: 403

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 403
Study: 37498273

Group type: EXPERIMENTAL
Intervention: Daily step count
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Floors climbed
Number of subjects: 425
Study: 32435908

Group type: EXPERIMENTAL
Intervention: Mechanical transnasal endoscopic DCR (MTE-DCR)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Transcanalicular dacryocystorhinostomy with multidiode laser (TCML-DCR)
Number of subjects: 29
Study: 32536496

Group type: EXPERIMENTAL
Intervention: Feedback training using PocketCPR
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Feedback training using Skill Reporter
Number of subjects: 64

Group type: COMPARATOR
Intervention: Non-feedback training (control group)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Feedback training (both methods)
Number of subjects: 64
Study: 34989637

Group type: EXPERIMENTAL
Intervention: Combination of a tourniquet and buffered lidocaine solution (CTB)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Wide awake local anesthesia no tourniquet (WALANT)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Conventional local anesthesia (LA)
Number of subjects: 169
Study: 32952089

Group type: EXPERIMENTAL
Intervention: 4-item likelihood of proactive use scale
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 4-item measure of confidence in use of insurance
Number of subjects: 0
Study: 34736360

Group type: EXPERIMENTAL
Intervention: 30% 1RM in hypoxia
Number of subjects: 15

Group type: COMPARATOR
Intervention: 30% 1RM in normoxia
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 70% 1RM in hypoxia
Number of subjects: 15

Group type: COMPARATOR
Intervention: 70% 1RM in normoxia
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 70% 1RM
Number of subjects: 15

Group type: COMPARATOR
Intervention: 30% 1RM
Number of subjects: 15
Study: 34496924

Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conservative medical treatment (control group)
Number of subjects: 80
Study: 35064301

Group type: EXPERIMENTAL
Intervention: TAP block
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study: 34015311

Group type: COMPARATOR
Intervention: Neoadjuvant durvalumab monotherapy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Neoadjuvant durvalumab plus stereotactic body radiotherapy (8 Gy × 3 fractions)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Neoadjuvant durvalumab plus stereotactic body radiotherapy
Number of subjects: 60
Study: 34953451

Group type: EXPERIMENTAL
Intervention: Swedish massage (30-min sessions, twice a week for first 4 weeks, three times a week for last 4 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 60
Study: 32989866

Group type: EXPERIMENTAL
Intervention: Cold atmospheric plasma (CAP) treatment once a week (Group 1)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Cold atmospheric plasma (CAP) treatment twice a week (Group 2)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo therapy once a week (Group 3)
Number of subjects: 37
Study: 34031890

Group type: EXPERIMENTAL
Intervention: Prednisone (50 mg for 7 days)
Number of subjects: 711

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 711
Study: 36216748

Group type: EXPERIMENTAL
Intervention: Sedentary behavior (30 minutes more)
Number of subjects: 1918

Group type: EXPERIMENTAL
Intervention: Light physical activity (30 minutes more)
Number of subjects: 1918

Group type: EXPERIMENTAL
Intervention: Sleep (30 minutes less)
Number of subjects: 1918
Study: 33992438

Group type: EXPERIMENTAL
Intervention: Saccharomyces cerevisiae recombinant hepatitis B vaccine (Group D20SC 0-1-6)
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Chinese hamster ovary cell (CHO) recombinant hepatitis B vaccine (Group D20CHO 0-1-6)
Number of subjects: 309

Group type: COMPARATOR
Intervention: Saccharomyces cerevisiae recombinant hepatitis B vaccine (Group ND20SC 0-1-6)
Number of subjects: 309
Study: 32416834

Group type: EXPERIMENTAL
Intervention: LASER
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Control
Number of subjects: 1200
Study: 34935711

Group type: EXPERIMENTAL
Intervention: Toric intraocular lens (TIOL) implantation
Number of subjects: 75

Group type: COMPARATOR
Intervention: Femtosecond laser‐assisted arcuate keratotomy (FSAK)
Number of subjects: 75
Study: 32602970

Group type: EXPERIMENTAL
Intervention: TARC-2 >800 pg/mL
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: TARC-2 ≤800 pg/mL
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: PET-2-negative patients with elevated TARC-2
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: PET-2-negative patients without elevated TARC-2
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: TARC-2 >800 pg/mL (whole study population)
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: TARC-2 >800 pg/mL (PET-2-negative patients)
Number of subjects: 266
Study: 32887560

Group type: EXPERIMENTAL
Intervention: Reinforced education via WeChat app
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 0
Study: 36281170

Group type: EXPERIMENTAL
Intervention: Low-dose doxepin (6.25 mg-12.5 mg per day) for 12 weeks
Number of subjects: 49
Study: 34551869

Group type: EXPERIMENTAL
Intervention: CT-P59 20 mg/kg
Number of subjects: 50
Study: 32713405

Group type: EXPERIMENTAL
Intervention: Food-specific ICT and if-then planning
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: General ICT and if-then planning
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: ICT and if-then planning (both groups)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: ICT and if-then planning
Number of subjects: 78
Study: 33518123

Group type: EXPERIMENTAL
Intervention: Temperature/RH combination of -15°C with uncontrolled RH for 8 hours
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Temperature/RH combination of 30°C with 80% RH for 8 hours
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Temperature/RH combination of 30°C with 30% RH for 8 hours
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Temperature/RH combinations (21/30, 21/80, 30/30, 30/80)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Duration of exposure (4 or 8 hours)
Number of subjects: 240
Study: 35446986

Group type: EXPERIMENTAL
Intervention: Treatment for PTSD
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Treatment for depression
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Treatment for PTSD and depression
Number of subjects: 318
Study: 33861314

Group type: EXPERIMENTAL
Intervention: Convolutional Neural Network (CNN) with HALO‐AI analysis
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Convolutional Neural Network (CNN) for autoimmune gastritis (AG)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Convolutional Neural Network (CNN) for Helicobacter pylori gastritis (HPG)
Number of subjects: 187

Group type: COMPARATOR
Intervention: GI pathologists
Number of subjects: 187

Group type: COMPARATOR
Intervention: General surgical pathologists
Number of subjects: 187

Group type: COMPARATOR
Intervention: Residents
Number of subjects: 187
Study: 35676030

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid (ω3FA) supplementation (4 g/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No ω3FA treatment (Control)
Number of subjects: 0
Study: 33894423

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (OXT)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo intranasal spray
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (decreased 5-HT signaling)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo control protocol (normal 5-HT signaling)
Number of subjects: 121
Study: 32349761

Group type: EXPERIMENTAL
Intervention: Sit-stand desk intervention (6 sit-stand desks replacing 3 standard desks for 4.5 months)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Usual practice control arm
Number of subjects: 176
Study: 35617462

Group type: EXPERIMENTAL
Intervention: Simulation-based TCCC tourniquet application training (Group A, n = 25)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Simulation-based TCCC tourniquet application training (Group B, n = 18)
Number of subjects: 43
Study: 33638278

Group type: EXPERIMENTAL
Intervention: Interactive online informational and peer support app for LARS
Number of subjects: 0
Study: 32323190

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg once daily
Number of subjects: 12729

Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 12729
Study: 33966671

Group type: EXPERIMENTAL
Intervention: Improved technique with glove change after each N95 contact
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 1‐minute ultraviolet‐C light (UV‐C) treatment prior to donning
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control with suboptimal respirator handling technique
Number of subjects: 12
Study: 33900373

Group type: EXPERIMENTAL
Intervention: Web-based educational intervention
Number of subjects: 119

Group type: COMPARATOR
Intervention: Upper GI tract endoscopy (control)
Number of subjects: 119
Study: 32998766

Group type: EXPERIMENTAL
Intervention: Ferritin-guided donation intervals policy (including ferritin measurements for all new donors and at every 5th whole blood donation, extending donation intervals to 6 months if ferritin is 15-≤ 30 ng/mL and to 12 months if ferritin is < 15 ng/mL)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Existing policy without ferritin measurements
Number of subjects: 29
Study: 34186022

Group type: EXPERIMENTAL
Intervention: Tirzepatide 5 mg
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: Tirzepatide 10 mg
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: Tirzepatide 15 mg
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: Tirzepatide (all doses)
Number of subjects: 478

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 478
Study: 32412419

Group type: EXPERIMENTAL
Intervention: FOOTFIT (nonexertive physical conditioning activities for lower leg function)
Number of subjects: 24

Group type: COMPARATOR
Intervention: FOOTFIT+ (FOOTFIT with added patient-provider communication feature)
Number of subjects: 24
Study: 36104378

Group type: EXPERIMENTAL
Intervention: Luseogliflozin (2.5 mg daily)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Voglibose (0.6 mg daily)
Number of subjects: 157
Study: 34118103

Group type: EXPERIMENTAL
Intervention: Wire rope guide with chin lift (wire group)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control technique of head flexion (control group)
Number of subjects: 100
Study: 32797232

Group type: EXPERIMENTAL
Intervention: C‐CIESI with triamcinolone
Number of subjects: 120

Group type: COMPARATOR
Intervention: CTFESI with dexamethasone
Number of subjects: 120
Study: 35369715

Group type: COMPARATOR
Intervention: Substernal chest pain (reference group)
Number of subjects: 9996

Group type: EXPERIMENTAL
Intervention: Dyspnea
Number of subjects: 9996

Group type: EXPERIMENTAL
Intervention: Other symptoms
Number of subjects: 9996

Group type: EXPERIMENTAL
Intervention: Positive noninvasive test
Number of subjects: 9996
Study: 34597324

Group type: EXPERIMENTAL
Intervention: CPAP ventilation and passive CPAP oxygenation
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control (no positive airway pressure)
Number of subjects: 68
Study: 35418599

Group type: EXPERIMENTAL
Intervention: Selenite 6 mg/l
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selenite 8 mg/l
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selenite 10 mg/l
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nano-selenium 12 mg/l
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (distilled water)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selenite 6 mg/l and 8 mg/l
Number of subjects: 0
Study: 33530059

Group type: EXPERIMENTAL
Intervention: X-Stop interspinous distractor device
Number of subjects: 47

Group type: COMPARATOR
Intervention: Laminectomy
Number of subjects: 47
Study: 36134907

Group type: EXPERIMENTAL
Intervention: Tissue flossing (FLOSS)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Foam rolling (ROLL)
Number of subjects: 32
Study: 34362264

Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: ICD shock (at least one)
Number of subjects: 90

Group type: COMPARATOR
Intervention: No ICD shock
Number of subjects: 90
Study: 32940343

Group type: EXPERIMENTAL
Intervention: Ixekizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fumaric acid esters
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 0
Study: 32663354

Group type: EXPERIMENTAL
Intervention: RFS-nomogram based on tumor size, differentiation, microscopic vascular invasion, preoperative α-fetoprotein, neutrophil-to-lymphocyte ratio, albumin-to-bilirubin ratio, and blood transfusion
Number of subjects: 1081

Group type: EXPERIMENTAL
Intervention: OS-nomogram based on tumor size, differentiation, microscopic vascular invasion, preoperative α-fetoprotein, neutrophil-to-lymphocyte ratio, albumin-to-bilirubin ratio, and blood transfusion
Number of subjects: 1081
Study: 35983622

Group type: EXPERIMENTAL
Intervention: Daprodustat
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control
Number of subjects: 50
Study: 33848778

Group type: EXPERIMENTAL
Intervention: bSPECT/CT imaging
Number of subjects: 43

Group type: COMPARATOR
Intervention: PET/CT imaging
Number of subjects: 43
Study: 34025030

Group type: EXPERIMENTAL
Intervention: Vonoprazan (20 mg/day)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Lansoprazole (30 mg/day)
Number of subjects: 216